Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review

BACKGROUND: Novel immunotherapy is one of the options for advanced biliary tract cancer (BTC) patients who are traditionally intolerant to chemotherapy. However, clinical evidence for single immunotherapy with pembrolizumab or nivolumab is limited. The present study assessed the safety and efficienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Tian, Zheng, Shanhua, Geng, Lei, Liu, Zhengtao, Xu, Jun, Lin, Bingyi, Qian, Junjie, Zheng, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739105/
https://www.ncbi.nlm.nih.gov/pubmed/33308041
http://dx.doi.org/10.1177/1533033820979703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739105/
https://www.ncbi.nlm.nih.gov/pubmed/33308041
http://dx.doi.org/10.1177/1533033820979703

Ejemplares similares